LeMaitre Vascular, Inc. (LMAT)

In Q3 2025, LeMaitre Vascular reported adjusted EPS of $0.62, surpassing estimates, but revenue slightly missed expectations. In February 2025, the company increased its quarterly dividend by 25% to $0.20 per share. There were instances of insider selling in August 2025 and July 2024. As of January 2026, analysts have given LMAT a consensus rating of "Moderate Buy," with an average 12-month target price of $100.20. Over the last 12 months, the stock price decreased by 9.18%, but it has seen a year-to-date return of 4.81% and increased by 1.19% in the past month.

LeMaitre Vascular's operating margin is subject to seasonal variations, indicating that the demand for their products and services may fluctuate throughout the year due to factors such as surgical schedules, hospital budgeting cycles, or other industry-specific trends.

LeMaitre Vascular, Inc. is a global medical device company specializing in products and services for the treatment of peripheral vascular disease, operating within the Healthcare sector, specifically in the Medical Instruments & Supplies industry. The company develops, manufactures, and markets disposable and implantable devices used by vascular surgeons in both open vascular surgeries and minimally invasive procedures. Their product portfolio addresses various anatomical areas, including the carotid, lower extremities, upper extremities, and aorta. Major products include allografts, catheters, biologic products, vascular grafts, carotid shunts, and other devices. The company also provides human tissue cryopreservation services through its RestoreFlow allograft business.

LeMaitre Vascular has a significant global presence, selling directly to hospitals in 25 countries and through distributors in more than 70 countries across North America, Europe, and the Asia/Pacific Rim. The company's headquarters are located in Burlington, Massachusetts, U.S.

LeMaitre Vascular maintains a strong market position in the peripheral vascular device market, focusing on specialized, high-margin open-surgery products. The company's mission emphasizes providing innovative devices to surgeons, which has contributed to its consistent demand and strong financial performance, including a high organic growth rate projected for 2025. There is no specific information available regarding events that have negatively impacted LeMaitre Vascular's brand reputation in the past year.

LeMaitre Vascular's ownership is predominantly institutional, with institutional investors holding a significant majority of the company's stock, well over 80% to 92.44% of outstanding shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Conestoga Capital Advisors, LLC. Insiders, including management and directors, maintain a notable stake, with George W. LeMaitre, Chairman and CEO, being the largest individual shareholder, owning approximately 7.88% of the company's shares.